학술논문
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
Document Type
Article
Author
Source
In Clinical Therapeutics February 2019 41(2):280-290
Subject
Language
ISSN
0149-2918